Introduction: Major depressive disorder (MDD) can impact the severity of allergic rhinitis (AR) and asthma (AA). Here, we evaluated the cytokine production by T-cells from AR and AA patients with or without MDD. The effect of serotonin on the in vitro T-cell response was also evaluated. Methods: The cytokines produced by activated T-cells were measured by Luminex and flow cytometry. In some cell cultures, serotonin was added. Results: MDD not only enhanced the production of Th2- and Th17-related cytokines, but also, the levels of interleukin (IL)-5 and IL-17 were directly correlated with the severity of depression and anxiety symptoms. As compared with AR, the levels of IL-17 were higher and the release of IL-10 was lower in activated T-cell cultures from AA patients, mainly those with MDD. In AA/MDD patients, the severity of anxiety symptoms and lung disease was directly correlated with Th17-like and hybrid Th2/Th17 cells, but inversely correlated with IL-10-secreting CD4+ T-cells. Finally, the addition of serotonin reduced the production of Th2- and Th17-related cytokines, but elevated IL-10 secretion in cell cultures from both AR and AA patients. Conclusions: Our findings suggest that not only the occurrence of MDD but also the severity of anxiety symptoms, may adversely affect the outcome of allergic reactions by favoring the production of cytokines implicated in the pathogenesis of AR and AA, a phenomenon that was attenuated by serotonin.

Keywords:
Allergy, Th17 cells, Th2 cells, Major depressive disorder, Serotonin
1.
Schatz M, Rosenwasser L. The allergic asthma phenotype.
J Allergy Clin Immunol Pract
. 2014 Nov–Dec;2(6):645–9.
2.
Colice GL. Categorizing asthma severity: an overview of national guidelines.
Clin Med Res
. 2004;2(3):155–63.
3.
Quirt J, Hildebrand KJ, Mazza J, Noya F, Kim H. Asthma.
Allergy Asthma Clin Immunol
. 2018;14(Suppl 2):50.
4.
Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013.
Ann Am Thorac Soc
. 2018;15:348–56.
5.
Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact.
Asthma Res Pract
. 2017;3:1.
6.
To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey.
BMC Public Health
. 2012;12:204.
7.
Lambrecht BN, Hammad H. The immunology of asthma.
Nat Immunol
. 2015;16:45–56.
8.
Walker JA, McKenzie ANJ. TH2 cell development and function.
Nat Rev Immunol
. 2018;18:121–33.
9.
Gowthaman U, Chen JS, Zhang B, Flynn WF, Lu Y, Song W, et al. Identification of a T follicular helper cell subset that drives anaphylactic IgE.
Science
. 2019;365:eaaw6433.
10.
Sutton BJ, Davies AM, Bax HJ, Karagiannis SN. IgE antibodies: from structure to function and clinical translation.
Antibodies
. 2019;8:19.
11.
Siebenhaar F, Redegeld FA, Bischoff SC, Gibbs BF, Maurer M. Mast cells as drivers of disease and therapeutic targets.
Trends Immunol
. 2018;39:151–62.
12.
Méndez-Enríquez E, Hallgren J. Mast cells and their progenitors in allergic asthma.
Front Immunol
. 2019;10:821.
13.
Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet-activating factor (PAF): a review of its role in asthma and clinical efficacy of PAF antagonists in the disease therapy.
Recent Pat Inflamm Allergy Drug Discov
. 2008;2:72–6.
14.
Liu M, Yokomizo T. The role of leukotrienes in allergic diseases.
Allergol Int
. 2015;64:17–26.
15.
Solelhac G, Charpin D. Management of allergic rhinitis.
F1000Prime Rep
. 2014;6:94.
16.
Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment.
J Allergy Clin Immunol
. 2017;139:438–47.
17.
Adcock IM, Marwick J, Casolari P, Contoli M, Fan Chung K, Kirkham P, et al. Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD).
Curr Pharm Des
. 2010;16:3554–73.
18.
Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severity.
Trends Immunol
. 2017;38:942–54.
19.
Newcomb DC, Peebles RS. Th17-mediated inflammation in asthma.
Curr Opin Immunol
. 2013;25:755–60.
20.
Morishima Y, Ano S, Ishii Y, Ohtsuka S, Matsuyama M, Kawaguchi M, et al. Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma.
Clin Dev Immunol
. 2013;2013:609395–9.
21.
Sun Y, Xu W. Peripheral blood Th17 and Th17/Th2 cells and their association with lung function and biomarkers in asthma-COPD overlap syndrome. In: Airway Cell Biology and Immunopathology. European Respiratory Society; 2017. p. PA1006.
22.
Hynes GM, Hinks TSC. The role of interleukin-17 in asthma: a protective response?
ERJ Open Res
. 2020;6.
23.
Östling J, van Geest M, Schofield JPR, Jevnikar Z, Wilson S, Ward J, et al. IL-17-high asthma with features of a psoriasis immunophenotype.
J Allergy Clin Immunol
. 2019;144:1198–213.
24.
Irvin C, Zafar I, Good J, Rollins D, Christianson C, Gorska MM, et al. Increased frequency of dual-positive TH2/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma.
J Allergy Clin Immunol
. 2014;134:1175–86.e7.
25.
Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, et al. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma.
J Exp Med
. 2010;207:2479–91.
26.
Chang HS, Lee TH, Jun JA, Baek AR, Park JS, Koo SM, et al. Neutrophilic inflammation in asthma: mechanisms and therapeutic considerations.
Expert Rev Respir Med
. 2017;11:29–40.
27.
Hirose K, Iwata A, Tamachi T, Nakajima H. Allergic airway inflammation: key players beyond the Th2 cell pathway.
Immunol Rev
. 2017;278:145–61.
28.
Al-Ramli W, Préfontaine D, Chouiali F, Martin JG, Olivenstein R, Lemière C, et al. TH17-associated cytokines (IL-17A and IL-17F) in severe asthma.
J Allergy Clin Immunol
. 2009;123:1185–7.
29.
Mukherjee M, Svenningsen S, Nair P. Glucocortiosteroid subsensitivity and asthma severity.
Curr Opin Pulm Med
. 2017;23:78–88.
30.
Zhao ST, Wang CZ. Regulatory T cells and asthma.
J Zhejiang Univ Sci B
. 2018;19:663–73.
31.
Yonas MA, Lange NE, Celedón JC. Psychosocial stress and asthma morbidity.
Curr Opin Allergy Clin Immunol
. 2012;12:202–10.
32.
Mohanan S, Tapp H, McWilliams A, Dulin M. Obesity and asthma: pathophysiology and implications for diagnosis and management in primary care.
Exp Biol Med
. 2014;239:1531–40.
33.
Choi HG, Kim JH, Park JY, Hwang YI, Jang SH, Jung KS. Association between asthma and depression: a national cohort study.
J Allergy Clin Immunol Pract
. 2019;7:1239–45.e1.
34.
Amritwar AU, Lowry CA, Brenner LA, Hoisington AJ, Hamilton R, Stiller JW, et al. Mental health in allergic rhinitis: depression and suicidal behavior.
Curr Treat Options Allergy
. 2017;4:71–97.
35.
Bedolla-Barajas M, Morales-Romero J, Pulido-Guillén NA, Robles-Figueroa M, Plascencia-Domínguez BR. Rhinitis as an associated factor for anxiety and depression amongst adults.
Braz J Otorhinolaryngol
. 2017;83:432–8.
36.
Akula M, Kulikova A, Khan DA, Brown ES. The relationship between asthma and depression in a community-based sample.
J Asthma
. 2018;55:1271–7.
37.
Sastre J, Crespo A, Fernandez-Sanchez A, Rial M, Plaza V, González FC, et al. Anxiety, depression, and asthma control: changes after standardized treatment.
J Allergy Clin Immunol Pract
. 2018;6:1953–9.
38.
Grosso A, Pesce G, Marcon A, Piloni D, Albicini F, Gini E, et al. Depression is associated with poor control of symptoms in asthma and rhinitis: a population-based study.
Respir Med
. 2019;155:6–12.
39.
Leonard BE. Inflammation and depression: a causal or coincidental link to the pathophysiology?
Acta Neuropsychiatr
. 2018;30:1–16.
40.
Liu CS, Adibfar A, Herrmann N, Gallagher D, Lanctôt KL. Evidence for inflammation-associated depression.
Curr Top Behav Neurosci
. 2016;31:3–30.
41.
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis.
Psychosom Med
. 2009;71:171–86.
42.
Halaris A, Meresh E, Fareed J, Hoppensteadt D, Kimmons S, Sinacore J. 2. Tumor necrosis factor alpha as a biomarker in major depressive disorder.
Brain Behav Immun
. 2012;26:S1.
43.
Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, et al. Immunomodulatory effects mediated by serotonin.
J Immunol Res
. 2015;2015:1–21.
44.
Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation.
Acta Physiol
. 2015;213:561–74.
45.
Herr N, Bode C, Duerschmied D. The effects of serotonin in immune cells.
Front Cardiovasc Med
. 2017;4:48.
46.
Sacramento PM, Monteiro C, Dias ASO, Kasahara TM, Ferreira TB, Hygino J, et al. Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4+ T-cell subsets in multiple sclerosis patients.
Eur J Immunol
. 2018;48:1376–88.
47.
Gomes-Oliveira MH, Gorenstein C, Lotufo Neto F, Andrade LH, Wang YP. Validation of the Brazilian Portuguese version of the Beck depression inventory-II in a community sample.
Braz J Psychiatry
. 2012;34:389–94.
48.
Quintão S, Delgado AR, Prieto G. Validity study of the Beck anxiety inventory (Portuguese version) by the Rasch Rating Scale model.
Psicol Reflex Crit
. 2013;26(2):305–10.
49.
Gjevre JA, Hurst TS, Taylor-Gjevre RM, Cockcroft DW. The American Thoracic Society’s spirometric criteria alone is inadequate in asthma diagnosis.
Can Respir J
. 2006;13:433–7.
50.
Ayuk AC, Ubesie A, Odimegwu CL, Iloh K. Use of global initiative for asthma (GINA) guidelines in asthma management among paediatric residents in a Sub Saharan African country: a cross-sectional descriptive study.
Pan Afr Med J
. 2017;27:120.
51.
Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders.
J Affect Disord
. 1988;14:61–8.
52.
Mottram P, Wilson K, Copeland J. Validation of the Hamilton Depression Rating Scale and Montgommery and Asberg Rating Scales in terms of AGECAT depression cases.
Int J Geriatr Psychiatry
. 2000;15:1113–9.
53.
Flachaire E, Beney C, Berthier A, Salandre J, Quincy C, Renaud B. Determination of reference values for serotonin concentration in platelets of healthy newborns, children, adults, and elderly subjects by HPLC with electrochemical detection.
Clin Chem
. 1990;36(12):2117–20.
54.
Lin SH, Lee LT, Yang YK. Serotonin and mental disorders: a concise review on molecular neuroimaging evidence.
Clin Psychopharmacol Neurosci
. 2014;12:196–202.
55.
Passali D, Cingi C, Staffa P, Passali F, Muluk NB, Bellussi ML. The International Study of the Allergic Rhinitis Survey: outcomes from 4 geographical regions.
Asia Pac Allergy
. 2018;8:e7.
56.
Sears MR. Trends in the prevalence of asthma.
Chest
. 2014;145(2):219–25.
57.
Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrländer C, et al. Exposure to environmental microorganisms and childhood asthma.
N Engl J Med
. 2011;364:701–9.
58.
Haahtela T, Laatikainen T, Alenius H, Auvinen P, Fyhrquist N, Hanski I, et al. Hunt for the origin of allergy: comparing the Finnish and Russian Karelia.
Clin Exp Allergy
. 2015;45:891–901.
59.
World Health Organization.
World Health Organization report:
depression and other common mental disorders:
global health estimates
. Geneva: World Health Organization; 2017.
60.
American Psychiatric Association.
Diagnostic and statistical manual of mental disorders
. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
61.
Acker WW, Plasek JM, Blumenthal KG, Lai KH, Topaz M, Seger DL, et al. Prevalence of food allergies and intolerances documented in electronic health records.
J Allergy Clin Immunol
. 2017;140:1587–91.e1.
62.
Leynaert B, Sunyer J, Garcia-Esteban R, Svanes C, Jarvis D, Cerveri I, et al. Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort.
Thorax
. 2012;67:625–31.
63.
Osman M, Hansell AL, Simpson CR, Hollowell J, Helms PJ. Gender-specific presentations for asthma, allergic rhinitis and eczema in primary care.
Prim Care Respir J
. 2007;16:28–35.
64.
Zou W, Feng R, Yang Y. Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression.
PLoS One
. 2018;13:e0197267.
65.
Ting EY, Yang AC, Tsai SJ. Role of interleukin-6 in depressive disorder.
Int J Mol Sci
. 2020;21:2194.
66.
Keaton SA, Madaj ZB, Heilman P, Smart L, Grit J, Gibbons R, et al. An inflammatory profile linked to increased suicide risk.
J Affect Disord
. 2019;247:57–65.
67.
Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
Lancet
. 2017;390:1211–59.
68.
Sambamoorthi U, Shah D, Zhao X. Healthcare burden of depression in adults with arthritis.
Expert Rev Pharmacoecon Outcomes Res
. 2017;17:53–65.
69.
Li Y-C, Chou Y-C, Chen H-C, Lu C-C, Chang D-M. Interleukin-6 and interleukin-17 are related to depression in patients with rheumatoid arthritis.
Int J Rheum Dis
. 2019;22(6):980–5.
70.
Wu Z, Fang Y. Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment.
Shanghai Arch Psychiatry
. 2014;26:227–31.
71.
Calzada D, Baos S, Cremades-Jimeno L, Cárdaba B. Immunological mechanisms in allergic diseases and allergen tolerance: the role of Treg cells.
J Immunol Res
. 2018;2018:6012053.
72.
Eckl-Dorna J, Villazala-Merino S, Campion NJ, Byazrova M, Filatov A, Kudlay D, et al. Tracing IgE-producing cells in allergic patients.
Cells
. 2019;8:994.
73.
Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in asthma and other eosinophilic disorders.
Front Med
. 2017;4:139.
74.
Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma.
Front Med
. 2018;5:49.
75.
Han MW, Kim SH, Oh I, Kim YH, Lee J. Serum IL-1β can be a biomarker in children with severe persistent allergic rhinitis.
Allergy Asthma Clin Immunol
. 2019;15:58.
76.
De Corso E, Baroni S, Battista M, Romanello M, Penitente R, Di Nardo W, et al. Nasal fluid release of eotaxin-3 and eotaxin-2 in persistent sinonasal eosinophilic inflammation.
Int Forum Allergy Rhinol
. 2014;4:617–24.
77.
Krause K, Metz M, Makris M, Zuberbier T, Maurer M. The role of interleukin-1 in allergy-related disorders.
Curr Opin Allergy Clin Immunol
. 2012;12:477–84.
78.
Gosset P, Tsicopoulos A, Wallaert B, Joseph M, Capron A, Tonnel AB. Tumor necrosis factor alpha and interleukin-6 production by human mononuclear phagocytes from allergic asthmatics after IgE-dependent stimulation.
Am Rev Respir Dis
. 1992;146:768–74.
79.
Tyurin YA, Lissovskaya SA, Fassahov RS, Mustafin IG, Shamsutdinov AF, Shilova MA, et al. Cytokine profile of patients with allergic rhinitis caused by pollen, mite, and microbial allergen sensitization.
J Immunol Res
. 2017;2017:3054217.
80.
Nobs SP, Kayhan M, Kopf M. GM-CSF intrinsically controls eosinophil accumulation in the setting of allergic airway inflammation.
J Allergy Clin Immunol
. 2019;143:1513–24.e2.
81.
Fleetwood AJ, Cook AD, Hamilton JA. Functions of granulocyte-macrophage colony-stimulating factor.
Crit Rev Immunol
. 2005;25(5):405–28.
82.
Soroosh P, Doherty TA. Th9 and allergic disease.
Immunology
. 2009;127:450–8.
83.
Zhou T, Huang X, Zhou Y, Ma J, Zhou M, Liu Y, et al. Associations between Th17-related inflammatory cytokines and asthma in adults: a case-control study.
Sci Rep
. 2017;7:15502.
84.
Fahy JV. Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies.
Proc Am Thorac Soc
. 2009;6(3):256–9.
85.
Wang J. Neutrophils in tissue injury and repair.
Cell Tissue Res
. 2018;371:531–9.
86.
Granger V, Taillé C, Roach D, Letuvé S, Dupin C, Hamidi F, et al. Circulating neutrophil and eosinophil extracellular traps are markers of severe asthma.
Allergy
. 2020;75:699–702.
87.
Han XA, Jie HY, Wang JH, Zhang XM, Wang J, Yu CX, et al. Necrostatin-1 ameliorates neutrophilic inflammation in asthma by suppressing MLKL phosphorylation to inhibiting NETs release.
Front Immunol
. 2020;11:666.
88.
Zijlstra GJ, ten Hacken NH, Hoffmann RF, van Oosterhout AJ, Heijink IH. Interleukin-17A induces glucocorticoid insensitivity in human bronchial epithelial cells.
Eur Respir J
. 2012;39:439–45.
89.
Fairbairn SM, Page CP, Lees P, Cunningham FM. Early neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure.
Clin Exp Allergy
. 1993;23:821–8.
90.
Schneider T, van Velzen D, Moqbel R, Issekutz AC. Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a Brown Norway rat model.
Am J Respir Cell Mol Biol
. 1997;17:702–12.
91.
Taube C, Dakhama A, Rha YH, Takeda K, Joetham A, Park JW, et al. Transient neutrophil infiltration after allergen challenge is dependent on specific antibodies and Fc gamma III receptors.
J Immunol
. 2003;170:4301–9.
92.
Vieira MM, Ferreira TB, Pacheco PA, Barros PO, Almeida CR, Araújo-Lima CF, et al. Enhanced Th17 phenotype in individuals with generalized anxiety disorder.
J Neuroimmunol
. 2010;229:212–8.
93.
Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): exploring its implications in infectious diseases.
Biomol Concepts
. 2018;9:64–79.
94.
D’Souza WN, Lefrançois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion.
J Immunol
. 2003;171:5727–35.
95.
Kawano Y, Noma T. Role of interleukin-2 and interferon-gamma in inducing production of IgG subclasses in lymphocytes of human newborns.
Immunology
. 1996;88:40–8.
96.
Andersson NW, Goodwin RD, Okkels N, Gustafsson LN, Taha F, Cole SW, et al. Depression and the risk of severe infections: prospective analyses on a nationwide representative sample.
Int J Epidemiol
. 2016;45:131–9.
97.
Carr TF, Kraft M. Chronic infection and severe asthma.
Immunol Allergy Clin North Am
. 2016;36:483–502.
98.
Pavón L, Sandoval-López G, Eugenia Hernández M, Loría F, Estrada I, Pérez M, et al. Th2 cytokine response in major depressive disorder patients before treatment.
J Neuroimmunol
. 2006;172:156–65.
99.
Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder.
Prog Neuropsychopharmacol Biol Psychiatry
. 2007;31:1044–53.
100.
Ford BN, Yolken RH, Dickerson FB, Teague TK, Irwin MR, Paulus MP, et al. Reduced immunity to measles in adults with major depressive disorder.
Psychol Med
. 2019;49:243–9.
101.
Burns VE, Drayson M, Ring C, Carroll D. Perceived stress and psychological well-being are associated with antibody status after meningitis C conjugate vaccination.
Psychosom Med
. 2002;64:963–70.
102.
Li Y, Xiao B, Qiu W, Yang L, Hu B, Tian X, et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder.
J Affect Disord
. 2010;124:68–75.
103.
Noval Rivas M, Chatila TA. Regulatory T cells in allergic diseases.
J Allergy Clin Immunol
. 2016;138:639–52.
104.
Waters RS, Perry JSA, Han S, Bielekova B, Gedeon T. The effects of interleukin-2 on immune response regulation.
Math Med Biol
. 2018;35:79–119.
105.
Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance.
Eur J Immunol
. 2010;40:1830–5.
106.
Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians?
World Psychiatry
. 2010;9:155–61.
107.
Müller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, et al. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and t-cell priming capacity of dendritic cells in vitro and in vivo.
PLoS One
. 2009;4:e6453.
108.
Snir O, Hesselberg E, Amoudruz P, Klares-kog L, Zarea-Ganji I, Catrina AI, et al. Genetic variation in the serotonin receptor gene affects immune responses in rheumatoid arthritis.
Genes Immun
. 2013;14:83–9.
109.
Chabbi-Achengli Y, Coman T, Collet C, Callebert J, Corcelli M, Lin H, et al. Serotonin is involved in autoimmune arthritis through Th17 immunity and bone resorption.
Am J Pathol
. 2016;186:927–37.
110.
Gałecki P, Mossakowska-Wójcik J, Talarowska M. The anti-inflammatory mechanism of antidepressants: SSRIs, SNRIs.
Prog Neuropsychopharmacol Biol Psychiatry
. 2018;80:291–4.
111.
Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis.
Brain Behav Immun
. 2019;79:24–38.
112.
Roumestan C, Michel A, Bichon F, Portet K, Detoc M, Henriquet C, et al. Anti-inflammatory properties of desipramine and fluoxetine.
Respir Res
. 2007;8:35.
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.